Ascletis Selects ASC37 as Its First Oral Triple Agonist for Obesity Treatment

Ascletis Selects ASC37 as Its First Oral Triple Agonist for Obesity Treatment

By, Admin 1 December 2025

Ascletis Pharma has taken a major step in its metabolic disease pipeline by selecting ASC37 oral tablets as a clinical development candidate. The company plans to submit an IND application to the US FDA in Q2 2026.

ASC37 is a GLP-1R/GIPR/GCGR triple peptide agonist developed using Ascletis’ in-house AI-driven drug discovery platform and its proprietary oral delivery technology.

Why ASC37 Matters?

ASC37 aims to solve a major industry challenge: How do you deliver a peptide drug orally with strong bioavailability and sustained exposure?

Ascletis believes ASC37 may be the answer.

Key highlights from non-human primate (NHP) studies:

  • 4.2% absolute oral bioavailability
  • 9× higher than semaglutide
  • 30× higher than tirzepatide
  • 60× higher than retatrutide
  • 57× higher drug exposure (AUC) than oral retatrutide
  • ~56-hour half-life, supporting once-daily or even less frequent dosing
  • 5×, 4×, and 4× more potent than retatrutide for GLP-1R, GIPR, and GCGR receptors

These results were achieved using the company’s POTENT oral transport technology.

The Science Behind ASC37

ASC37 is built using three of Ascletis’ core technology platforms:

  • AISBDD (AI-Assisted Structure-Based Drug Discovery)
  • POTENT (Peptide Oral Transport ENhancement Technology)
  • ULAP (Ultra-Long-Acting Platform)

Together, they enabled the creation of an oral triple agonist with strong potency and long systemic exposure.

What the Leadership Says?

Jinzi Jason Wu, Ph.D., Founder, Chairman, and CEO of Ascletis, commented:

“Selecting ASC37 shows our strong R&D engine and commitment to solving obesity. Our technology platforms allow us to build a differentiated and competitive metabolic pipeline.”

The GRP: A Growing Obesity Pipeline

ASC37 is part of a broader metabolic portfolio, which includes:

  • ASC30 – Oral and long-acting GLP-1R agonist
  • ASC36 – Once-monthly amylin receptor agonist
  • ASC35 – Once-monthly GLP-1R/GIPR dual agonist
  • ASC37 – Oral GLP-1R/GIPR/GCGR triple agonist

Ascletis continues to position itself as a key innovator in obesity and metabolic disorders.

Upcoming Milestone

A Mandarin investor call is scheduled for December 1, 2025, via Tencent/VooV Meeting (ID: 495-266-842).

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!